Hello, again. And how are you this morning? A beautiful day is unfolding here on the Pharmalot corporate campus - the birds are chirping, the official mascots are lounging about and the cup of stimulation is brewing. Meanwhile, we are looking forward to another day of R&D. We know you can relate. To help you along, here are some tidbits. Hope your day goes well and stay in touch...
Vertex Tops Merck In Hep C Drug Launch (The Street)
Glaxo R&D Chief Says Advair Is Safe From Generics (Reuters)
J&J Plans To Market More Products Under The Janssen Name (Financial Times)
New Prostate Cancer Drugs Are Expensive (New York Times)
Amgen Sells $3 Billion In Bonds To Pay For Dividends (Bloomberg News)
Diabetes Cases In Adults Worldwide Has Doubled In 30 Years (Reuters)
India Suspends Axis Clinical's License (Outsourcing Pharma)
Lilly Plans To Hire 40 Scientists (Indianapolis Star)
More Doctors Are Turning Away Insured Patients (Bloomberg News)
J&J And Gilead To Develop Combination HIV Drug (Reuters)
Vertex And Merck Ads Focus On Hepatitis C, Not Drugs (Boston Globe)
Curaxis Pharma Overhauls Management And Board (Raleigh News & Observer)
Transdel Pharma Files For Bankruptcy (San Diego Union-Tribune)
EDITOR’S NOTE: Please check this post for updates throughout the morning
sunrise pic thx to benimoto on flickr
4 Comments
Ed,
"New Prostate Cancer Drugs Are Expensive (New York Times)" --
Surely this isn't from NYT, but rather from the prestigious Journal of the Bleedin' Obvious?
Cheers,
Pete
The costs of these drugs to society needs to be placed in perspective. Using the NY Times own data, only about 15% of prostate cancer patients (about 32,000) are even candidates for these therapies in the first place. Worst case scenario. Give all 32K Provenge, at $93K/course of treatment. Comes to roughly $3 billion, only a small fraction of the Medicare budget. Better we should do something about cost inefficiencies in hospice management and selection, also cited in today's paper. Somehow we've gone from less than six months to live to some patients spending up to five years in a hospice.
Janssen! we're completely different from McNeil! no, really!
20% of the comments on the Indystar.com article re Lilly hirings were blocked by the editorial staff. Must be a few unhappy campers in Naptown.